THERAPEUTIC OPTIONS IN DERMATOMYOSITIS/POLYMYOSITIS
1994; Wiley; Volume: 33; Issue: 4 Linguagem: Inglês
10.1111/j.1365-4362.1994.tb01034.x
ISSN1365-4632
AutoresAlan S. Boyd, Kenneth H. Neldner,
Tópico(s)Dermatological and Skeletal Disorders
ResumoInternational Journal of DermatologyVolume 33, Issue 4 p. 240-250 THERAPEUTIC OPTIONS IN DERMATOMYOSITIS/POLYMYOSITIS ALAN S. BOYD M.D., Corresponding Author ALAN S. BOYD M.D. From the Departments of Dermatology, The University of Texas Medical School at Houston, Houston, Texas, and Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas.Address for correspondence: Alan S. Boyd, M.D., Department of Dermatology, 3900 The University of Texas Medical School at Houston, Houston, TX 37232–5227.Search for more papers by this authorKENNETH H. NELDNER M.D., KENNETH H. NELDNER M.D. From the Departments of Dermatology, The University of Texas Medical School at Houston, Houston, Texas, and Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas.Search for more papers by this author ALAN S. BOYD M.D., Corresponding Author ALAN S. BOYD M.D. From the Departments of Dermatology, The University of Texas Medical School at Houston, Houston, Texas, and Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas.Address for correspondence: Alan S. Boyd, M.D., Department of Dermatology, 3900 The University of Texas Medical School at Houston, Houston, TX 37232–5227.Search for more papers by this authorKENNETH H. NELDNER M.D., KENNETH H. NELDNER M.D. From the Departments of Dermatology, The University of Texas Medical School at Houston, Houston, Texas, and Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas.Search for more papers by this author First published: April 1994 https://doi.org/10.1111/j.1365-4362.1994.tb01034.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Spencer CH, Hanson V, Singsen BH, et al. Course of treated juvenile dermatomyositis. J Pediatr 1984; 105: 399– 408. 2 Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). J Am Acad Dermatol 1991; 24: 959– 966. 3 Rose AL. Childhood polymyositis: a follow-up study with special reference to treatment with corticosteroids. Am J Dis Child 1974; 127: 518– 522. 4 Mulder DW, Winkelmann RK, Lambert EH, et al. Steroid therapy in patients with polymyositis and dermatomyositis. Ann Intern Med 1963; 58: 969– 976. 5 Wedgewood RJP, Cook CD, Cohen J. Dermatomyositis: report of 26 cases in children with a discussion of endocrine therapy in 13. Pediatrics 1953; 12: 447– 466. 6 Tuffanelli DL, Lavole PE. Prognosis and therapy of polymyositis/dermatomyositis. Clin Dermatol 1988; 6: 93– 104. 7 Bohan A, Peter JB, Bowman RL, et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56: 255– 286. 8 Bowyer SL, Blane CE, Sullivan DB, et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 882– 888. 9 Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12: 1140– 1148. 10 Carpenter JR, Bunch TW, Engel AG, et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977; 4: 207– 214. 11 Miller JJ. Late progression in dermatomyositis in childhood. J Pediatr 1973; 83: 543– 548. 12 Miller G, Heckmatt JZ, Dubowitz V. Drug treatment of juvenile dermatomyositis. Arch Dis Child 1983; 58: 445– 450. 13 Dubowitz V. Treatment of dermatomyositis in childhood. Arch Dis Child 1976; 51: 494– 550. 14 Pachman LM, Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr 1980; 96: 226– 234. 15 Winkelmann RK. Dermatomyositis in childhood. Clin Rheum Dis 1982; 8: 353– 368. 16 Sullivan DB, Cassidy JT, Petty RE, et al. Prognosis in childhood dermatomyositis. J Pediatr 1972; 80: 555– 563. 17 Oddis CV, Medsger TA. Current management of polymyositis and dermatomyositis. Drugs 1989; 37: 382– 390. 18 Fink CW. Overview of corticosteroid therapy in the treatment of rheumatic diseases of childhood. Clin Exp Dermatol 1991; 9(Suppl 6): 9– 13. 19 Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 1986; 15: 231– 254. 20 Hoffman GS, Franck WA, Raddatz DA, et al. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital. Am J Med 1983; 75: 433– 438. 21 Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics 1977; 59: 212– 218. 22 Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182– 189. 23 Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 403– 407. 24 Niakan E, Pitner SE, Whitaker JN, et al. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology 1980; 30: 286– 291. 25 Janssens S, Decramer M. Corticosteroid-induced myopathy and the respiratory muscles. Chest 1989; 95: 1160– 1162. 26 Yanagisawa T, Sueishi M, Nawata Y, et al. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica 1983; 167: 47– 51. 27 Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30: 328– 334. 28 Miller JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989– 994. 29 Pachman LM. Juvenile dermatomyositis. Pediatr Clin North Am 1986; 33: 1097– 1117. 30 Ramirez G, Asherson RA, Khamashta MA, et al. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990; 20: 114– 120. 31 Haas DC. Treatment of polymyositis with immunosupressive drugs. Neurology 1973; 23: 55– 62. 32 Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid resistant dermatomyositisp/olymyositis. Arthritis Rheum 1985; 28: 590– 592. 33 Tiliakos NA. Low-dose cytotoxic combination treatment in intractable dermatopolymyositis (DM/PM). Arthritis Rheum 1987; 30: 514 (Abstr). 34 Hollingworth P, de Vere Tymlall A, Ansell BM, et al. Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 1982; 41: 557– 562. 35 Sokoloff MC, Goldberg LS, Pearson CM. Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet 1971; i: 14– 16. 36 Fischer TJ, Rachelefsy GS, Klein RB, et al. Childhood dermatomyositis and polymyositis. Am J Dis Child 1979; 133: 386– 389. 37 Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet 1968; ii: 485– 488. 38 Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979; 115: 1251– 1252. 39 Fries JF, Sharp GC, McDevitt HO, et al. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum 1973; 16: 154– 162. 40 Bombardieri S, Hughes GRV, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; i: 1138– 1139. 41 Cronin ME, Miller FW, Hicks JE, et al. Failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myositis. I Rheumatol 1989; 16: 1225– 1228. 42 Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis dermatomyositis. J Rheumatol 1989; 16: 1592– 1596. 43 Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Arch Neurol 1981; 38: 544– 552. 44 Rapini RP. Cytotoxic drugs in the treatment of skin disease. Int J Dermatol 1991; 30: 313– 322. 45 McFarlin DE, Griggs RC. Treatment of inflammatory myopathies with azathioprine. Trans Am Neurol Assoc 1968; 93: 244– 246. 46 Benson MD, Aldo MA. Azathioprine therapy in polymyositis. Arch Intern Med 1973; 132: 547– 551. 47 Bunch TW, Worthington JW, Combs JJ et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980; 92: 365– 369. 48 Roifman CM, Schaffer FM, Wachsmuth SE, et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513– 515. 49 Gelfand EW. Use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy. J Allergy Clin Immunol 1989; 84: 613– 616. 50 Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162– 168. 51 Morita R, Nakano K, Hirano Y, et al. Dramatic effects of high-dose intravenous gammaglobulin in each patient with intractable dermatomyositis and polymyositis. No To Hattatsu 1989; 21: 523– 528. 52 Cherin P, Herson S, Wechsler B, et al. Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients. Press. Med 1991; 20: 244– 249. 53 Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169– 172. 54 Gupta AK, Brown MD, Ellis CN, et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989; 21: 1245– 1256. 55 Zabel P, Leimenstoll G, Gross WL. Cyclosporine for acute dermatomyositis. Lancet 1984; i: 343. 56 Ejstrup L. Severe dermatomyositis treated with cyclosporine A. Ann Rheum Dis 1986; 45: 612– 613. 57 Girardin E, Dayer JM, Paunier L. Cyclosporine for juvenile dermatomyositis. J Pediatr 1988; 112: 165– 166. 58 Casato M, Bonomo L, Caccavo D, Giorgi A. Clinical effects of cyclosporine in dermatomyositis. Clin Exp Dermatol 1990; 15: 121– 123. 59 Dantzig P. Juvenile dermatomyositis treated with cyclosporine. J Am Acad Dermatol 1990; 22: 310– 311. 60 Kavanagh GM, Ross JS, Black MM. Dermatomyositis treated with Cyclosporine. J R Soc Med 1991; 84: 306. 61 Levi S, Hodgson HJF. Cyclosporine for dermatomyositis Ann Rheum Dis 1989; 48: 85– 86. 62 Jones EW, Snaith ML, Isenberg DA. Cyclosporine treatment for intractable polymyositis. Arthritis Rheum 1987; 30: 959– 960. 63 Danko K, Szegedi G. Cyclosporine A treatment of dermatomyositis. Arthritis Rheum 1991; 34: 933– 934. 64 Heckmatt J, Hasson N, Saunders C, et al. Cyclosporine in juvenile dermatomyositis. Lancet 1989; i: 1063– 1066. 65 Anderson L, Ziter FA. Plasmapheresis via central catheter in dermatomyositis: a new method for selected pediatric patients. J Pediatr 1981; 98: 240– 241. 66 Dau PC, Bennington JL. Plasmapheresis in childhood dermatomyositis. J Pediatr 1981; 98: 237– 240. 67 Brewer EJ, Giannini EH, Rossen RD, et al. Plasma exchange therapy of a childhood onset dermatomyositis patient. Arthritis Rheum 1980; 23: 509– 513. 68 Herson L, Lok C, Roujeau JC, et al. Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange. Ann Med Interne (Paris) 1989; 140: 453– 455. 69 Lok C, Herson S, Roujeau JC, et al. Plasma exchange in dermatomyositis. A retrospective study of 21 cases. Ann Dermatol Venereol 1989; 116: 219– 224. 70 Bennington JL, Dau PC. Patients with polymyositis and dermatomyositis who undergo plasmapheresis therapy. Arch Neurol 1981; 38: 553– 560. 71 Lane RJM, Hudgson P. Thymectomy in polymyositis. Lancet 1984; i: 626. 72 Cumming WJK. Thymectomy in refractory dermatomyositis. Muscle Nerve 1989; 12: 424. 73 Engel WK, Lichter AS, Galdi AP. Polymyositis: remarkable response to total body irradiation. Lancet 1981; i: 658. 74 Schon F, Thomas PK, Senanayake LF. Remission from polymyositis after total body irradiation. Br Med J 1982; 285: 290. (Letter). 75 Morgan SH, Bernstein RM, Coppen J, et al. Total body irradiation and the course of polymyositis. Arthritis Rheum 1985; 28: 831– 835. 76 Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve 1988; 11: 120– 123. 77 Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxyl-chloroquine. J Am Acad Dermatol 1984; 10: 592– 600. 78 James WD, Dawson N, Rodman OG. Treatment of dermatomyositis with hydroxychloroquine. J Rheumatol 1985; 12: 1214– 1216. 79 Olson NY, Lindsley CB. Adjunctive use of hydroxyl-chloroquine in childhood dermatomyositis. J Rheumatol 1989; 16: 1545– 1547. 80 Sewell JR, Liyanage B, Ansell BM. Calcinosis in juvenile dermatomyositis. Skeletal Radiol 1978; 3: 137– 143. 81 Bassett CAL, Donath A, Macagno F, et al. Diphosphonates in the treatment of myositis ossificans. Lancet 1969; ii: 845. 82 Russell RGG, Smith R. Diphosphonates: experimental and clinical aspects. J Bone Joint Surg 1973; 55B: 66– 86. 83 Weiss IW, Fisher L, Phang JM. Diphosphonate therapy in a patient with myositis ossificans progressive. Ann Intern Med 1971; 74: 933– 936. 84 Cram RL, Barmada R, Geho WB, et al. Diphosphonate treatment of calcinosis universalis. N Engl J Med 1971; 285: 1012– 1013. 85 Metzger AL, Singer FR, Bluestone R, et al. Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N Engl J Med 1974; 291: 1294– 1296. 86 Berger RG, Featherstone GL, Raasch RH, et al. Treatment of calcinosis universalis with low-dose heparin. Am J Med 1987; 83: 72– 76. 87 Berger RG, Hadler NM. Treatment of calcinosis universalis secondary to dermatomyositis or scleroderma with low dose warfarin. Arthritis Rheum 1983; 26: 511. (Abstr). 88 Lassoued K, Saiag P, Anglade MC, et al. Failure of warfarin in treatment of calcinosis universalis. Am J Med 1988; 84: 795– 796. 89 Nassim JR, Connolly CK. Treatment of calcinosis universalis with aluminium hydroxide. Arch Dis Child 1970; 45: 118– 121. 90 Wang WJ, Lo WL, Wong CK, et al. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol 1988; 124: 1721– 1722. 91 Skuterud E, Sydnes OA, Haavik TK. Calcinosis in dermatomyositis treated with probenecid. Scand J Rheumatol 1981; 10: 92– 94. 92 Herd JK, Vaughan JH. Calcinosis universalis complicating dermatomyositis—its treatment with Na2EDTA. Arthritis Rheum 1964; 7: 259– 271. 93 Dent CE, Stamp TCB. Treatment of calcinosis circumscripta with probenecid. Br Med J 1972; 1: 216– 218. 94 Taborn J, Bole GG, Thompson GR. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med 1978; 89: 648– 649. 95 Carlson M, Lindseth RE, DeRosa GP. Surgical removal of soft tissue calcifications in dermatomyositis. Arch Surg 1975; 110: 755– 756. 96 England MJ, Perlmann T, Veriava Y. Dermatomyositis in pregnancy. J Reprod Med 1986; 31: 633– 636. 97 King CR, Chow S. Dermatomyositis and pregnancy. Obstet Gynecol 1985; 66: 589– 592. 98 Mintz G. Dermatomyositis. Rheum Dis Clin North Am 1989; 15: 375– 382. 99 Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992; 326: 363– 367. 100 Barnes BE. Dermatomyositis and malignancy. Ann Intern Med 1976; 84: 68– 76. 101 Harris AL, Smith IE, Snaith M. Tamoxifen-induced tumour regression associated with dermatomyositis. Br Med J 1982; 284: 1674– 1675. 102 Adachi JD, Bensen WG, Craig GL, et al. A randomized control trial of vitamin D and calcium in steroid-induced osteoporosis. Arthritis Rheum 1987; 30: S14. (Abstr). 103 Rejou F, Dumas R, Belon C, et al. Fluoride treatment in corticosteroid-induced osteoporosis. Arch Dis Child 1986; 61: 1230– 1231. 104 Pollock JL. Toxoplasmosis appearing to be dermatomyositis. Arch Dermatol 1979; 115: 736– 737. 105 Topi GC, D'Alessandro L, Catricala C, et al. Dermatomyositis-like syndrome due to toxoplasma. Br J Dermatol 1979; 101: 589– 591. 106 Harland CC, Marsdenn JR, Vernon SA, Allen BR. Dermatomyositis responding to treatment of associated toxoplasmosis. Br J Dermatol 1991; 125: 76– 78. 107 Peterson J, Halberg P, Højgaard K, et al. Penicillamine-induced polymyositis-dermatomyositis. Scand J Rheumatol 1978; 7: 113– 117. 108 Curran JJ, Jamieson TW. Dermatomyositis-like syndrome associated with phenylbutazone therapy. J Rheumatol 1987; 14: 397– 398. 109 Grob JJ, Collet AM, Bonerandi JJ. Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents. Dermatologica 1989; 178: 58– 59. 110 Fusella J, Strosberg JM. Polymyositis exacerbated by gemfibrozil. J Rheumatol 1990; 17: 572– 573. Citing Literature Volume33, Issue4April 1994Pages 240-250 ReferencesRelatedInformation
Referência(s)